-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
With the advancement of the volume procurement policy, centralized procurement objects have gradually extended from chemical drugs to biosimilar drugs, proprietary Chinese medicines, and even equipment, consumables and other fields
.
In this context, the market is pessimistic about the pharmaceutical industry at this stage, but many institutions believe that rational judgments should be exercised, such as focusing on the subdivision of the pharmaceutical industry for centralized procurement and immunity.
Specific areas worthy of attention include CXO, pharmaceutical equipment, and so on
.
Which segments of the pharmaceutical industry will be immune to centralized procurement? Two directions are worth paying attention to (Image source: Pharmaceutical Network) CXO field has high growth certainty.
CXO refers to pharmaceutical contract outsourcing services, including CRO, CMO and CDMO three sub-industries, known as the "water sellers of the pharmaceutical industry" "
.
The industry generally believes that the CXO field is one of the few industries in the pharmaceutical industry that is immune to centralized procurement
.
In recent years, with the acceleration of new drug approvals, domestic innovative drug research and development are in full swing.
Data shows that in 2020, there will be 1,448 new innovative drug clinical applications in China, an increase of more than 70% year-on-year
.
Benefiting from innovation-driven clinical demand, the transfer of overseas industrial chains to China, and the support of favorable policies, the growth of the CXO industry has a high degree of certainty
.
According to the Frost & Sullivan report, by 2022, the market size of new drug R&D outsourcing services will grow to US$178.
5 billion
.
Other data predict that by 2025, the CXO market is expected to reach US$244 billion
.
Southwest Securities also pointed out that, driven by cost advantages, overseas CXO production capacity continues to shift to China, and the rise of domestic innovative drugs further brings incremental space for the CXO industry.
It is expected that the performance of the CXO sector is expected to maintain rapid growth with high certainty.
It is recommended to pay attention Platform-based CXO enterprise with integrated industrial chain layout
.
The agency recommends the giants WuXi AppTec, small molecule CDMO Chemtech, Proton Co.
, Ltd.
, Jiuzhou Pharmaceutical and Haoyuan Pharmaceutical, which realize the integration of CRO+CDMO, and it is recommended to pay attention to Kanglong Chemical, Tigermed and Wise Pharmaceuticals, etc.
.
Increasing demand for pharmaceutical equipment Pharmaceutical equipment belongs to the upstream field of the pharmaceutical industry.
The industry believes that although from the perspective of supply, pharmaceutical equipment belongs to the category of special equipment manufacturing, since its main demand comes from the pharmaceutical industry, it is also possible to start with demand.
Classify it as an alternative pharmaceutical stock
.
In recent years, with the emergence of a major wave of bio-innovative drugs and raw material drug CDMOs, and the gradual expansion of domestic drugs to overseas markets, the production lines of domestic pharmaceutical companies have continued to expand their production capacity and upgrade, driving the increase in demand for pharmaceutical equipment, and the market scale will continue to expand
.
The data shows that the domestic pharmaceutical equipment market has exceeded 100 billion yuan in 2020, and it is expected to continue to maintain an industry growth rate of about 14% in the future.
By 2024, this market will exceed 170 billion yuan
.
At present, the pharmaceutical equipment industry is entering a stage of strategic incremental opportunities.
The order structure of leading companies such as Chutian Technology and Tofflon continues to improve, and the driving force for performance growth is more diversified, which will drive high-speed growth in future performance
.
For example, Tofflon's performance in the first half of 2021 has improved significantly, mainly due to the gradual effect of the diversified layout of products in the pharmaceutical equipment sector.
Among them, the bioengineering sector, injection stand-alone and system sectors, medical equipment and consumables sectors have increased by approximately 600%, 16.
2%, 138%; Chutian Technology's revenue, net profit and other indicators in the first half of this year have risen sharply, and the support of operating performance is inseparable from the contributions of many product sectors.
Among them, testing packaging solutions and The stand-alone business, bioengineering solutions and stand-alone business segments increased by 135.
42% and 255.
41% year-on-year respectively
.
.
In this context, the market is pessimistic about the pharmaceutical industry at this stage, but many institutions believe that rational judgments should be exercised, such as focusing on the subdivision of the pharmaceutical industry for centralized procurement and immunity.
Specific areas worthy of attention include CXO, pharmaceutical equipment, and so on
.
Which segments of the pharmaceutical industry will be immune to centralized procurement? Two directions are worth paying attention to (Image source: Pharmaceutical Network) CXO field has high growth certainty.
CXO refers to pharmaceutical contract outsourcing services, including CRO, CMO and CDMO three sub-industries, known as the "water sellers of the pharmaceutical industry" "
.
The industry generally believes that the CXO field is one of the few industries in the pharmaceutical industry that is immune to centralized procurement
.
In recent years, with the acceleration of new drug approvals, domestic innovative drug research and development are in full swing.
Data shows that in 2020, there will be 1,448 new innovative drug clinical applications in China, an increase of more than 70% year-on-year
.
Benefiting from innovation-driven clinical demand, the transfer of overseas industrial chains to China, and the support of favorable policies, the growth of the CXO industry has a high degree of certainty
.
According to the Frost & Sullivan report, by 2022, the market size of new drug R&D outsourcing services will grow to US$178.
5 billion
.
Other data predict that by 2025, the CXO market is expected to reach US$244 billion
.
Southwest Securities also pointed out that, driven by cost advantages, overseas CXO production capacity continues to shift to China, and the rise of domestic innovative drugs further brings incremental space for the CXO industry.
It is expected that the performance of the CXO sector is expected to maintain rapid growth with high certainty.
It is recommended to pay attention Platform-based CXO enterprise with integrated industrial chain layout
.
The agency recommends the giants WuXi AppTec, small molecule CDMO Chemtech, Proton Co.
, Ltd.
, Jiuzhou Pharmaceutical and Haoyuan Pharmaceutical, which realize the integration of CRO+CDMO, and it is recommended to pay attention to Kanglong Chemical, Tigermed and Wise Pharmaceuticals, etc.
.
Increasing demand for pharmaceutical equipment Pharmaceutical equipment belongs to the upstream field of the pharmaceutical industry.
The industry believes that although from the perspective of supply, pharmaceutical equipment belongs to the category of special equipment manufacturing, since its main demand comes from the pharmaceutical industry, it is also possible to start with demand.
Classify it as an alternative pharmaceutical stock
.
In recent years, with the emergence of a major wave of bio-innovative drugs and raw material drug CDMOs, and the gradual expansion of domestic drugs to overseas markets, the production lines of domestic pharmaceutical companies have continued to expand their production capacity and upgrade, driving the increase in demand for pharmaceutical equipment, and the market scale will continue to expand
.
The data shows that the domestic pharmaceutical equipment market has exceeded 100 billion yuan in 2020, and it is expected to continue to maintain an industry growth rate of about 14% in the future.
By 2024, this market will exceed 170 billion yuan
.
At present, the pharmaceutical equipment industry is entering a stage of strategic incremental opportunities.
The order structure of leading companies such as Chutian Technology and Tofflon continues to improve, and the driving force for performance growth is more diversified, which will drive high-speed growth in future performance
.
For example, Tofflon's performance in the first half of 2021 has improved significantly, mainly due to the gradual effect of the diversified layout of products in the pharmaceutical equipment sector.
Among them, the bioengineering sector, injection stand-alone and system sectors, medical equipment and consumables sectors have increased by approximately 600%, 16.
2%, 138%; Chutian Technology's revenue, net profit and other indicators in the first half of this year have risen sharply, and the support of operating performance is inseparable from the contributions of many product sectors.
Among them, testing packaging solutions and The stand-alone business, bioengineering solutions and stand-alone business segments increased by 135.
42% and 255.
41% year-on-year respectively
.
